Results 11 to 20 of about 265,748 (319)

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

MMWR. Morbidity and mortality weekly report, 2023
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the
K. Fleming-Dutra, Jefferson M. Jones, Lauren Roper, M. Prill, Ismael R. Ortega-Sanchez, Danielle L. Moulia, Megan Wallace, Monica Godfrey, Karen R. Broder, Naomi K. Tepper, O. Brooks, Pablo J. Sánchez, Camille N. Kotton, Barbara E. Mahon, Sarah S. Long, M. McMorrow   +15 more
semanticscholar   +1 more source

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source

Seasonality of Respiratory Syncytial Virus — United States, 2017–2023

MMWR. Morbidity and mortality weekly report, 2023
In the United States, respiratory syncytial virus (RSV) infections cause an estimated 58,000-80,000 hospitalizations among children aged
Sarah Hamid, A. Winn, Rishika Parikh, Jefferson M. Jones, M. McMorrow, M. Prill, B. Silk, Heather M. Scobie, A. Hall   +8 more
semanticscholar   +1 more source

Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation

Cureus, 2023
With an increasing global incidence in children younger than the age of five, respiratory syncytial virus (RSV) is one of the most common viral respiratory infections worldwide. Despite the increasing number of cases among infants and young children, RSV
Jasndeep Kaler, Azhar Hussain, Kishan V. Patel, T. Hernandez, S. Ray   +4 more
semanticscholar   +1 more source

SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses

The Lancet, 2022
Measures to reduce transmission of SARS-CoV-2 have also been effective in reducing the transmission of other endemic respiratory viruses. As many countries decrease the use of such measures, we expect that SARS-CoV-2 will circulate with other respiratory
Maaike C. Swets, C. Russell, E. Harrison, A. Docherty, Nazir Lone, M. Girvan, H. Hardwick, L. Visser, P. Openshaw, G. Groeneveld, M. Semple, J. Baillie   +11 more
semanticscholar   +1 more source

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.

Lancet. Infectious Diseases (Print), 2022
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
N. Mazur, J. Terstappen, R. Baral, A. Bardají, P. Beutels, U. Buchholz, C. Cohen, J. Crowe, C. Cutland, Linda Eckert, D. Feikin, Tiffany Fitzpatrick, Y. Fong, B. Graham, T. Heikkinen, Deborah Higgins, S. Hirve, K. Klugman, L. Kragten-Tabatabaie, P. Lemey, R. Libster, Y. Löwensteyn, A. Mejías, F. Muñoz, P. Munywoki, L. Mwananyanda, H. Nair, M. Nunes, O. Ramilo, P. Richmond, T. Ruckwardt, Charles J. Sande, P. Srikantiah, N. Thacker, Kody A. Waldstein, D. Weinberger, J. Wildenbeest, D. Wiseman, H. Zar, M. Zambon, L. Bont   +40 more
semanticscholar   +1 more source

Possible respiratory syncytial virus infection presenting as diffuse alveolar hemorrhage in an elderly treated with systemic corticosteroid: A case report

Respiratory Medicine Case Reports, 2021
Introduction: Respiratory syncytial virus infection is gaining interest in the elderly due to its growing morbidity and mortality. We present a Case of respiratory syncytial virus infection presenting as diffuse alveolar hemorrhage that was highly ...
Kyung Hun Nam, MD MPH, Junho Kang, MD, Younsuck Koh, MD PhD FCCM   +2 more
doaj   +1 more source

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children

JAMA Network Open, 2023
This systematic review and network meta-analysis compares the efficacy and safety of 4 monoclonal antibodies for preventing respiratory syncytial virus among infants and children.
Mingyao Sun, H. Lai, Feiyang Na, Sheng Li, Xia Qiu, Jinhui Tian, Zhigang Zhang, L. Ge   +7 more
semanticscholar   +1 more source

The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019-Related Public Health Measures.

Clinical Infectious Diseases, 2021
To the Editor—Yeoh et al reported the dramatic impact of public health measures introduced during the coronavirus disease 2019 (COVID-19) pandemic on influenza and respiratory syncytial virus (RSV) detections in Western Australian (WA) children [1]. Here,
D. Foley, D. Yeoh, C. Minney-Smith, Andrew C Martin, A. Mace, C. Sikazwe, Huong Le, A. Levy, H. Moore, C. Blyth   +9 more
semanticscholar   +1 more source

Estimated impact of maternal vaccination on global paediatric influenza-related in-hospital mortality: A retrospective case series

EClinicalMedicine, 2021
Background: Influenza virus infection is an important cause of under-five mortality. Maternal vaccination protects children younger than 3 months of age from influenza infection.
Yvette N Löwensteyn, Harish Nair, Marta C Nunes, Ichelle van Roessel, Femke S Vernooij, Joukje Willemsen, Louis J Bont, Natalie I Mazur   +7 more
doaj   +1 more source